Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Intangibles data on file, last reported at $174.0 million in Q1 2026.

• Quarterly Intangibles fell 1.43% year-over-year to $174.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $174.0 million (down 1.43% YoY) and the FY2025 annual result came in at $176.0 million, down 1.12% from the prior year.
• Intangibles retreated to $174.0 million in Q1 2026 per RARE's latest filing, from $176.0 million in the prior quarter.
• Across five years, Intangibles topped out at $178.0 million in Q4 2024 and bottomed at $157.3 million in Q3 2023.
• The 5-year median for Intangibles is $165.0 million (2024), against an average of $166.3 million.
• The widest annual swing landed in 2022, when Intangibles advanced 22.42%; it then retreated 1.43% in 2026.
• Tracing RARE's Intangibles over 5 years: stood at $160.1 million in 2022, then rose by 3.85% to $166.3 million in 2023, then grew by 7.05% to $178.0 million in 2024, then decreased by 1.12% to $176.0 million in 2025, then slipped by 1.14% to $174.0 million in 2026.
• Per Business Quant, the three latest RARE Intangibles figures stand at $174.0 million (Q1 2026), $176.0 million (Q4 2025), and $172.9 million (Q3 2025).

Peer Comparison